{"id":"NCT03512262","sponsor":"Radius Health, Inc.","briefTitle":"Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of Abaloparatide-SC for the Treatment of Men With Osteoporosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-05-03","primaryCompletion":"2021-08-17","completion":"2021-09-08","firstPosted":"2018-04-30","resultsPosted":"2023-04-07","lastUpdate":"2023-04-07"},"enrollment":228,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Osteoporosis","Osteoporosis, Age-Related","Osteoporosis Localized to Spine","Age Related Osteoporosis","Osteoporosis Senile","Osteoporosis of Vertebrae"],"interventions":[{"type":"DRUG","name":"Abaloparatide","otherNames":["TYMLOSÂ®","BA058","abaloparatide-SC"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Abaloparatide","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"A 12-month study to measure the efficacy and safety of abaloparatide in men with osteoporosis.","primaryOutcome":{"measure":"Percent Change From Baseline in Lumbar Spine BMD at Month 12","timeFrame":"Baseline, Month 12","effectByArm":[{"arm":"Abaloparatide","deltaMin":8.482,"sd":0.5353},{"arm":"Placebo","deltaMin":1.1654,"sd":0.7235}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"40 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":10},"locations":{"siteCount":34,"countries":["United States","Italy","Poland"]},"refs":{"pmids":["11241160","10564229","8119233"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":149},"commonTop":["Injection site erythema","Nasopharyngitis","Dizziness","Upper respiratory tract infection","Back pain"]}}